Pacira BioSciences, Inc.
PCRX
$25.99
$0.632.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 705.85M | 702.77M | 700.97M | 694.96M | 690.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 705.85M | 702.77M | 700.97M | 694.96M | 690.31M |
| Cost of Revenue | 201.57M | 204.49M | 217.16M | 220.53M | 223.14M |
| Gross Profit | 504.28M | 498.29M | 483.81M | 474.43M | 467.17M |
| SG&A Expenses | 329.30M | 308.85M | 294.10M | 280.29M | 273.90M |
| Depreciation & Amortization | 57.29M | 57.29M | 57.29M | 57.29M | 57.29M |
| Other Operating Expenses | 351.00K | 351.00K | -- | -- | -- |
| Total Operating Expenses | 637.41M | 612.49M | 603.39M | 592.95M | 589.18M |
| Operating Income | 68.44M | 90.29M | 97.57M | 102.01M | 101.13M |
| Income Before Tax | -106.55M | -68.04M | -63.11M | -54.91M | 100.55M |
| Income Tax Expenses | 20.91M | 35.69M | 36.45M | 35.82M | 36.95M |
| Earnings from Continuing Operations | -127.46 | -103.73 | -99.56 | -90.73 | 63.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.46M | -103.73M | -99.56M | -90.73M | 63.59M |
| EBIT | 68.44M | 90.29M | 97.57M | 102.01M | 101.13M |
| EBITDA | 158.43M | 171.81M | 176.36M | 178.03M | 175.34M |
| EPS Basic | -2.77 | -2.25 | -2.16 | -1.97 | 1.37 |
| Normalized Basic EPS | 0.84 | 1.29 | 1.36 | 1.41 | 1.37 |
| EPS Diluted | -2.79 | -2.29 | -2.20 | -1.99 | 1.34 |
| Normalized Diluted EPS | 0.81 | 1.23 | 1.27 | 1.30 | 1.23 |
| Average Basic Shares Outstanding | 184.04M | 184.75M | 184.98M | 185.24M | 185.53M |
| Average Diluted Shares Outstanding | 187.16M | 192.24M | 197.90M | 200.93M | 206.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |